All In Biotech

Drug Trial Radar · NCT06885567

A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

A Multicenter, Randomized, Double-blind, Parallel Design, Placebo-controlled, Phase 2 Clinical Trial and Open-Label Extension Study to Evaluate the Safety and Efficacy for BEY2153 in Patients with Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 2025

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Lead sponsor
BeyondBio Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.

Conditions

  • Alzheimer Disease
  • Alzheimer' Disease

Interventions

  • BEY2153Drug

    Participants administer once daily, PO, 26 weeks

  • PlaceboDrug

    Participants administer once daily, PO, 26 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline until 4 weeks after the end of treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea

  • SMG-SNU Boramae Medical Center

    Seoul, South Korea

  • Yeouido St. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.